MedrxMedrx Co., Ltd.4586東証グロース医薬品FY ending Dec 2025, consolidated, J-GAAP

Medrx FY ending Dec 2020 results

Medrx brought in ¥115.1M in revenue.

It lost about ¥982 for every ¥100 of sales at the operating level.

Revenue changed -32.2% from the prior year.

What changed from last year

FY ending Dec 2019 → FY ending Dec 2020

Revenue
-32.2%¥169.9M → ¥115.1M
Gross profit
-32.5%¥164.6M → ¥111.2M
Operating income
Loss-¥1.63B → -¥1.13B
Net income attributable to owners
Loss-¥1.62B → -¥1.11B
Operating cash flow
Loss-¥1.55B → -¥985.4M
Free cash flow
Loss-¥1.8B → -¥1.02B

Where the money goes

FY ending Dec 2019 → FY ending Dec 2020

Where ¥100 of sales goes

For every ¥100 Medrx sells, how much goes where, and how much is kept.

FY ending Dec 2020
Cost of sales
¥3
SG&A
¥1079
Operating loss
¥982
Net loss
¥968

Annual margin trends

Gross margin96.6%
FY ending Dec 2019: 96.9%96.9%FY ending Dec 2020: 96.6%96.6%FY19FY20
Operating margin-982.2%
FY ending Dec 2019: -958.4%-958.4%FY ending Dec 2020: -982.2%-982.2%FY19FY20
Net margin-968.5%
FY ending Dec 2019: -951.6%-951.6%FY ending Dec 2020: -968.5%-968.5%FY19FY20

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Sources

Show source documents (5)
  • EDINET (FSA Japan)

    有価証券報告書-第23期(2024/01/01-2024/12/31)

    ID S100VJ6C2025-03-31Open
  • EDINET (FSA Japan)

    有価証券報告書-第22期(2023/01/01-2023/12/31)

    ID S100T6BL2024-03-29Open
  • EDINET (FSA Japan)

    有価証券報告書-第21期(2022/01/01-2022/12/31)

    ID S100QGPL2023-03-28Open
  • EDINET (FSA Japan)

    有価証券報告書-第20期(令和3年1月1日-令和3年12月31日)

    ID S100NT3I2022-03-31Open
  • EDINET (FSA Japan)

    訂正有価証券報告書-第19期(令和2年1月1日-令和2年12月31日)

    ID S100LCUR2021-05-18Open

Extracted from XBRL: 39 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.